Design of new chemicals entities as selective COX-2 inhibitors using structure optimization by molecular modeling studies

Internet Electronic Journal of Molecular Design

Volumn 8, Issue 2, 2009, Pages 14-28

  Bhandari, Shashikant ^a   Bothara, Kailash ^a   Pawar, Vidya ^a   Lokwani, Deepak ^a   Devale, Titiksh ^a  

^a AISSMS COLLEGE OF PHARMACY   (India)

Author keywords

3D QSAR; COX 2; Cyclooxygenase 2; Diaryl imidazole; Molecular field analysis

Indexed keywords

EID: 77952490570     PISSN: None     EISSN: 15386414     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. A. Burger, Burgers Medicinal Chemistry and Drug Discovery, John WILY and Sons, Inc., NewYork; 5th Edition 1995, 3-4.
2. K. D. Rainsford, The ever-emerging anti-inflammatories. Have there been any real advances, J. Physiol. Paris 2001, 95, 11-19.
3. R. W. Dubois, G. Y. Melmad, L. Laine, and J. M. Henning, Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy, Ailment Pharmacol. Ther. 2004, 19, 197-208.
4. S. V. Bhandari, and M. K. Raut, www.pharmainfo.net/exclusive/review/current_advances_in_rheumatoidarthritis_therapy_a_Review.
5. J. L. Wallance, and A. G. Buret, www.gastro.org/user-asset/documents/08-publications/06-GIHEP_Annual-Review/Articles/Wallace-Buret.pdf.
6. G. Dannhart, and W. Kiefer, Cyclooxygenase inhibitors - current status and future prospects, Eur. J. Med. Chem. 2001, 36,109-126.
7. R. G. Kurumbail, A. M. Stevens, J. K. Gierse, J. J. McDonald, R. A. Stegeman, D. Glide-haus, J. M. Miyashiro, T. D. Pening, K. Seibert, P. C. Isakson, and W. C. Stallings, Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents, Nature. 1996, 384, 644.
8. A. Raz, A. Wyche, N. Siegel, and P. Nedleeman, Regulation of fibroblast Cyclooxygenase synthesis by interleukin-1, J. Biol. Chem. 1988, 263, 3022-3028.
9. D. W. Read, W. S. Bradshaw, W. Xie, and D. L. Simmons, In vivo and in vitro expression of a non-mammalian cyclooxygenase-1, Prostaglandins. 1996, 52, 269.
10. A. S. Kalguttkar, B. C. Crews, S. W. Rowlinson, C. Garner, K. Seibert, and L. J. Marnett, Aspirin-like Molecules that Covalently Inactivate Cyclooxygenase-2, Science.1998, 280, 1268.
11. N. M. Davies, Toxicity of nonsteroidal anti-inflammatory drugs in the large intestine, Diseases of colon and rectum. 1995, 38, 1311.
12. M. D. Murry, and D. C. Brater, Renal Toxicity of the Nonsteroidal Anti-Inflammatory Drugs, Annu. Rev. Pharm. Toxicol. 1993, 33, 435.
13. J. H. Botting, Nonsteroidal Antiinflammatory Agents, Drugs Today 1999, 35, 225.
14. T. D. Penning, J. J. Tally, S. R. Bertenshaw, J. S. Carter, P. W. Collins, S. Doctor, M. J. Graneto, L. F. Lee, J. W. Malecha, J. M. Miyashiro, R. S. Rogers, D. J. Rogier, S. S. Yu, G. D. Anderson, E. G. Burton, J. N. Congburn, S. A. Gregory, C. M. Koboldt, W. E. Perkins, K. Seibert, A. W. Veenhuizen, Y. Y. Zhang, and P. C. Isakson, Synthesis and Biological Evaluation of the 1,5-Diarylpyrazole Class of Cyclooxygenase-2 Inhibitors:# Identification of 4-[5-(4-Methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide (SC-58635, Celecoxib), J. Med. Chem. 1997, 40, 1347.
15. P. Prasit, Z. Wang, C. Brideau, C. C. Chan, S. Charleson, W. Cromlish, D. Ethier, J. F. Evans, A. W. Ford-Hutchinson, J. Y. Gauthier, R. Gordon, J. Guay, M. Gresser, S. Kargman, B. Kennedy, Y. Leblanc, S. Leger, J. Mancini, G. P. O'Neill, M. Ouellet, M. D. Percival, H. Perrier, D. Riendeau, I. W. Rodger, P. Tagari, M. Therien, P. Vickers, E. Wong, L. J. Xu, R. N. Young, R. Zambani, S. Boyce, N. Rupniak, M. Forest, D. Visco, and D Patrick, The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4_-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor, Bioorg. Med Chem.Lett. 1999, 9, 1773.
16. J. J. Talley, D. L. Brown, J. S. Carter, M. J. Graneto, C. M. Koboldt, J. L. Masferrer, W. E. Perkins, R. S. Rogers, A. F. Shaffer, Y. Y. Zhang, B. S. Zweiefel, K. L. Sebert, 4-[5-Methyl-3-phenylisoxazol-4-yl] benzenesulfonamide, Valdecoxib:_A Potent and Selective Inhibitor of COX-2, J. Med. Chem. 2000, 43, 775.
17. J. Talley, S. R. Bertenshaw, D. L. Brown, J. S. Carter, M. J. Graneto, M. S. Kellogg, C. M. Koboldt, J. Yuan, Y. Y. Zhang, and K. Seibert, N-[[(5-Methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl]propanamide, Sodium Salt, Parecoxib Sodium: A Potent and Selective Inhibitor of COX-2 for Parenteral Administration, J. Med. Chem. 2000, 43, 1661.
18. T. R. Sharpe, S. C. Cherkofsky, W. E. Hewes, D. H. Smith, W. A. Gregory, S. B. Haber, M. R. Leadbetter, and J. G. Whitney, Preparation, antiarthritic and analgesic activity of 4,5-diaryl-2-(substituted thio)-1H-imidazoles and their sulfoxides and sulfones, J Med. Chem. 1985, 28, 1188-1194.
19. VLIfeMDS, Molecular Design Suit Version 2.0, V-Life Science TechnologiesPvt.LTD. Pune, Indian, 2004, (www.Vlifesciences.com).
20. C. Hansch, and A. Leo: In Exploring QSAR, American Chemical Society, Washington, DC, 1995, 19.
21. S. Ajmani, K. Jadhav, and S. Kulkarni: Three-Dimensional QSAR Using the k-Nearest Neighbor Method and Its Interpretation, J. Comp. Inf. Model. 2006, 46, 24-31.
22. T. A. Halgren, Merck molecular force field. II. MMFF94 van der Waals and electrostatic parameters for intermolecular interactions, J. Comp. Chem. 1996, 17, 520-552.